FDA's CDER Addresses 'Challenges of Globalization' With a New Office
20/6/2011
In recognition of the difficulties presented by a rapidly expanding global drug market, FDA’s Center for Drug Evaluation and Research (CDER) has created a new office “dedicated to addressing the challenges of globalization and an increasingly complex drug supply chain,” according to memo sent by CDER director Janet Woodcock.
Author: Greer Deal, Director of Global Regulatory Services (GRS)